Compare Microchip Technology Inc. (MCHP) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Organon & Co. Common Stock — how do they compare? Microchip Technology Inc. trades at $69.92 (market cap $40.27B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Microchip Technology Inc. is far larger — about 11.1× Organon & Co. Common Stock's market cap, and Microchip Technology Inc. pays the higher dividend (2.45%). Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 63 Days and Organon & Co. Common Stock for 0 Days on average.
| MCHP | OGN | |
|---|---|---|
Market Cap | $40.27B | $3.62B |
Volume | 6,570,711 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $102.97 | $13.81 |
52-Week Low | $49.02 | $5.70 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $45.40B | $11.04B |
Dividend Yield | 2.45% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $71.25, down 3.49% today, with a bearish technical signal from moving averages. The company shows mixed fundamentals with strong recent earnings beats but negative net income in 2025. Recent developments include the acquisition of Hailo and expansion of Ethernet and power portfolios targeting automotive and data center markets. Analyst consensus remains strongly bullish with a $110.50 price target despite current weakness.
MCHP faces near-term headwinds from cyclical semiconductor demand but maintains long-term growth potential through AI infrastructure and automotive connectivity. High valuation ratios (P/E 109.06) and significant debt ($5.63B) present risks, while institutional accumulation and product expansion provide upside catalysts. The stock offers 55% upside to consensus target if execution improves.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
